Filing Information

Inventor(s)	Ching-Shih Chen ·
Assignee(s)	THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION ·  View assignee updates
Correspondent	CALFEE HALTER & GRISWOLD, LLP ·
Application Number	US12476772
Filing date	06/02/2009
Publication date	11/12/2009
Predicted expiration date	10/04/2024
U.S. Classifications	548/254  · 548/377.1  ·
International Classifications	C07D23112  · C07D40312  ·
Kind Code	A1

Patent Family

Abstract

A new class of phosphoinositide-dependent kinase-1 (PDK-1) inhibitors of formula I: wherein X is selected from the group consisting of alkyl and haloalkyl; Ar is an aryl radical selected from the group consisting of phenyl, biphenyl, naphthyl, anthryl, phenanthryl, and fluorenyl; and wherein Ar is optionally substituted with one or more radicals selected from the group consisting of halo, C1-C4 alkyl, C1-C4 haloalkyl, azido, C1-C4 azidoalkyl, aryl, alkylaryl, haloaryl, haloalkylaryl, and combinations thereof; and R is selected from the group consisting of nitrile, acetonitrile, ethylnitrile, propylnitrile, carboxamide, amidine, tetrazole, oxime, hydrazone, acetamidine, aminoacetamide, guanidine, and urea. Also provided are methods of using the compounds for the treatment and prevention of cancer in humans.

Independent Claims | See all claims (17)

1. 1. A compound of formula I wherein X is selected from the group consisting of alkyl and haloalkyl; Ar is selected from the group consisting of phenyl, biphenyl, naphthyl, anthryl, phenanthrenyl, and fluorenyl; wherein Ar is optionally substituted with one or more substituents at any suitable position, R is selected from the group consisting of, —CH2CN, —CH2CH2CN, —CH2CH2CH2CN or metabolites or pharmaceutically acceptable salts thereof.
2. 6. (canceled)
3. 10. A compound of formula II X is selected from the group consisting of alkyl and haloalkyl; R is selected from the group consisting of —CN, —CH2CN, —CH2CH2CN, —CH2CH2CH2CN or metabolites or pharmaceutically acceptable salts thereof.
4. 14. A compound of formula III: R is selected from the group consisting of —CN, —CH2CN, —CH2CH2CN, —CH2CH2CH2CN—CONH2 or metabolites or pharmaceutically acceptable salts thereof.
5. 15-16. (canceled)
6. 18-19. (canceled)